Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Главный автор: | Akter, Anika |
---|---|
Другие авторы: | Alam, Marzia |
Формат: | Диссертация |
Язык: | English |
Опубликовано: |
Brac University
2022
|
Предметы: | |
Online-ссылка: | http://hdl.handle.net/10361/17039 |
Схожие документы
-
Biologics and Biosimilars as Treatment Options for Psoriasis
по: Moya, Amena Khatun
Опубликовано: (2023) -
Importance of biologics in rheumatoid arthritis management
по: Riyadh, S. M.
Опубликовано: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
по: Afroza, Halima
Опубликовано: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
по: Mehreen, Elnaj
Опубликовано: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
по: Islam, Nahidul
Опубликовано: (2023)